A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine

Inclusion Criteria: * A female between, and including, 9-13 years (before 14th birthday) and 16-26 years of age (before 27th birthday) at the time of the first vaccination. * Healthy * Not pregnant * Four or less sexual partners over lifetime as reported by subject. (Sexual activity is defined as intercourse) * Not planning to become pregnant or likely to become pregnant * No reported history of genital warts * No laboratory confirmed history of cervical intraepithelial neoplasia * No previous vaccination against HPV * No administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period * No previous anaphylactic reaction to HPV vaccine or any vaccine related component including aluminum hydroxyphosphate sulfate and polysorbate 80 * No confirmed or suspected immunosuppressive or immunodeficient condition based on medical history * No bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection. * Cannot be already enrolled in any clinical trial in which investigational vaccine or drug are being administered Exclusion Criteria * Pregnant * Female planning to become pregnant or likely to become pregnant (as determined by the investigator) during the study duration Part 1 (0-7 months) * Reported history of genital warts * Laboratory confirmed history of cervical intraepithelial neoplasia * Greater than four lifetime sexual partners involving sexual intercourse * Previous vaccination against HPV * Administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period * A previous anaphylactic reaction to HPV vaccine or any vaccine related component including aluminum hydroxyphosphate sulfate and polysorbate 80 * Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history (e.g. HIV infection, genetic defect, immunosuppressive therapy). \*Chronic administration (defined as more than 14 days) of immune-modifying drugs within 6 months prior to the first vaccine dose or planned use during the study period is exclusionary (corticosteroid use - immune-modifying level is ≥0.5 mg/kg/day; inhaled or topical steroids are acceptable). * Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection (thrombocytopaenia, coagulation disorder, anti-coagulant therapy). * Enrollment in any clinical trial in which investigational vaccine or drug are being administered